AMSC-derived Exosomes Alleviate Lipopolysaccharide/d-galactosamine-induced Acute Liver Failure by MiR-17-mediated Reduction of TXNIP/NLRP3 Inflammasome Activation in Macrophages

Overview

Journal EBioMedicine

Specialty Biomedical Engineering

Date 2018 Sep 11

PMID 30197023

Citations 108

Authors

Yanning Liu

Guohua Lou

Aichun Li

Tianbao Zhang

Jinjin Qi

Dan Ye

Min Zheng

Zhi Chen

Affiliations

Soon will be listed here.

Abstract

Background: Mesenchymal stem cell (MSC)-derived exosome administration has been considered as a novel cell-free therapy for liver diseases through cell-cell communication. This study was aimed to determine the effects and mechanisms of AMSC-derived exosomes (AMSC-Exo) for acute liver failure (ALF) treatment.

Methods: AMSC-Exo were intravenously administrated into the mice immediately after lipopolysaccharide and D-galactosamine (LPS/GalN)-exposure and their effects were evaluated by liver histological and serum biochemical analysis. To elucidate its mechanisms in ALF therapy, the expression levels of miRNAs and inflammasome-related genes in macrophages were evaluated by qPCR and Western blot analysis, respectively. The exosomes from miR-17-knockdowned AMSCs (AMSC-Exo) were used for further determine the role of miR-17 in AMSC-Exo-based therapy.

Findings: AMSC-Exo administration significantly ameliorated ALF as determined by reduced serum alanine aminotransferase and aspartate aminotransferase levels and hepatic inflammasome activation. Further experiments revealed that AMSC-Exo were colocalized with hepatic macrophages and could reduce inflammatory factor secretion by suppressing inflammasome activation in macrophages. Moreover, miR-17, which can suppress NLRP3 inflammasome activation by targeting TXNIP, was abundant in AMSC-Exo cargo. While, the therapeutic effects of AMSC-Exo on ALF were significantly abolished as they could not effectively suppress TXNIP expression and consequent inflammasome activation in vitro and in vivo.

Interpretation: Exosome-shuttled miR-17 plays an essential role in AMSC-Exo therapy for ALF by targeting TXNIP and suppressing inflammasome activation in hepatic macrophages. AMSC-Exo-based therapy may present as a promising approach for TXNIP/NLRP3 inflammasome-related inflammatory liver diseases. FUND: Key R&D projects of Zhejiang province (2018C03019) and National Natural Science Fund (81470851 and 81500616).

Citing Articles

Mesenchymal stem cell-derived small extracellular vesicles reduced hepatic lipid accumulation in MASLD by suppressing mitochondrial fission.

Chen Y, Yang F, Wang Y, Shi Y, Liu L, Luo W Stem Cell Res Ther. 2025; 16(1):116.

PMID: 40045380 PMC: 11884000. DOI: 10.1186/s13287-025-04228-2.

Bone Marrow Mesenchymal Stem Cell-Originated Exosomes Curb Oxidative Stress and Pyroptosis Triggered by Ovarian Ischemia/Reperfusion via the TXNIP/NLRP3 Inflammasome Pathway.

Xu M, Don M, Chen Y, Zhang M Appl Biochem Biotechnol. 2025; .

PMID: 40042757 DOI: 10.1007/s12010-025-05188-2.

Mesenchymal stem cells-derived exosomes attenuate mouse non-heart-beating liver transplantation through Mir-17-5p-regulated Kupffer cell pyroptosis.

Tian Y, Jin M, Ye N, Gao Z, Jiang Y, Yan S Stem Cell Res Ther. 2025; 16(1):57.

PMID: 39920844 PMC: 11806715. DOI: 10.1186/s13287-025-04169-w.

Advances in the treatment of liver injury based on mesenchymal stem cell-derived exosomes.

Hu C, Wang L Stem Cell Res Ther. 2024; 15(1):474.

PMID: 39696473 PMC: 11657567. DOI: 10.1186/s13287-024-04087-3.

The Opportunities and Challenges of Mesenchymal Stem Cells-Derived Exosomes in Theranostics and Regenerative Medicine.

Yadav S, Maity P, Kapat K Cells. 2024; 13(23).

PMID: 39682706 PMC: 11640604. DOI: 10.3390/cells13231956.

References

Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J . Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2009; 11(2):136-40. DOI: 10.1038/ni.1831. View

Schroder K, Tschopp J . The inflammasomes. Cell. 2010; 140(6):821-32. DOI: 10.1016/j.cell.2010.01.040. View

Bauernfeind F, Rieger A, Schildberg F, Knolle P, Schmid-Burgk J, Hornung V . NLRP3 inflammasome activity is negatively controlled by miR-223. J Immunol. 2012; 189(8):4175-81. DOI: 10.4049/jimmunol.1201516. View

Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L . Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 2012; 22(6):845-54. PMC: 3585469. DOI: 10.1089/scd.2012.0395. View

Tan C, Lai R, Wong W, Dan Y, Lim S, Ho H . Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther. 2014; 5(3):76. PMC: 4229780. DOI: 10.1186/scrt465. View

Liu Y, Lian K, Zhang L, Wang R, Yi F, Gao C . TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol. 2014; 109(5):415. DOI: 10.1007/s00395-014-0415-z. View

Volarevic V, Nurkovic J, Arsenijevic N, Stojkovic M . Concise review: Therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis. Stem Cells. 2014; 32(11):2818-23. DOI: 10.1002/stem.1818. View

Colombo M, Raposo G, Thery C . Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30:255-89. DOI: 10.1146/annurev-cellbio-101512-122326. View

Negash A, Gale Jr M . Hepatitis regulation by the inflammasome signaling pathway. Immunol Rev. 2015; 265(1):143-55. DOI: 10.1111/imr.12279. View

10.

Hyun J, Wang S, Kim J, Kim G, Jung Y . MicroRNA125b-mediated Hedgehog signaling influences liver regeneration by chorionic plate-derived mesenchymal stem cells. Sci Rep. 2015; 5:14135. PMC: 4569897. DOI: 10.1038/srep14135. View

11.

Lou G, Song X, Yang F, Wu S, Wang J, Chen Z . Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma. J Hematol Oncol. 2015; 8:122. PMC: 4627430. DOI: 10.1186/s13045-015-0220-7. View

12.

Dong D, Fu N, Yang P . MiR-17 Downregulation by High Glucose Stabilizes Thioredoxin-Interacting Protein and Removes Thioredoxin Inhibition on ASK1 Leading to Apoptosis. Toxicol Sci. 2015; 150(1):84-96. PMC: 4830238. DOI: 10.1093/toxsci/kfv313. View

13.

Ju C, Tacke F . Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. Cell Mol Immunol. 2016; 13(3):316-27. PMC: 4856798. DOI: 10.1038/cmi.2015.104. View

14.

Wang T, Wang Z, Yang P, Xia L, Zhou M, Wang S . PER1 prevents excessive innate immune response during endotoxin-induced liver injury through regulation of macrophage recruitment in mice. Cell Death Dis. 2016; 7:e2176. PMC: 4855679. DOI: 10.1038/cddis.2016.9. View

15.

Liu X, Wang T, Liu X, Cai L, Qi J, Zhang P . Biochanin A protects lipopolysaccharide/D-galactosamine-induced acute liver injury in mice by activating the Nrf2 pathway and inhibiting NLRP3 inflammasome activation. Int Immunopharmacol. 2016; 38:324-31. DOI: 10.1016/j.intimp.2016.06.009. View

16.

He Y, Hara H, Nunez G . Mechanism and Regulation of NLRP3 Inflammasome Activation. Trends Biochem Sci. 2016; 41(12):1012-1021. PMC: 5123939. DOI: 10.1016/j.tibs.2016.09.002. View

17.

Alvarado R, To J, Lund M, Pinar A, Mansell A, Robinson M . The immune modulatory peptide FhHDM-1 secreted by the helminth Fasciola hepatica prevents NLRP3 inflammasome activation by inhibiting endolysosomal acidification in macrophages. FASEB J. 2016; 31(1):85-95. DOI: 10.1096/fj.201500093R. View

18.

Woolbright B, Jaeschke H . Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure. J Hepatol. 2016; 66(4):836-848. PMC: 5362341. DOI: 10.1016/j.jhep.2016.11.017. View

19.

Shin T, Kim H, Kang T, Lee B, Lee H, Kim Y . Human umbilical cord blood-stem cells direct macrophage polarization and block inflammasome activation to alleviate rheumatoid arthritis. Cell Death Dis. 2016; 7(12):e2524. PMC: 5260999. DOI: 10.1038/cddis.2016.442. View

20.

Yu X, Lan P, Hou X, Han Q, Lu N, Li T . HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1β production via suppressing the NF-κB pathway and ROS production. J Hepatol. 2016; 66(4):693-702. DOI: 10.1016/j.jhep.2016.12.018. View